Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Breast Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Breast Cancer
    Metabolic Factors May Play a Role in Risk for Breast Cancer - (DGNews)
    TopAbstracts in Breast Cancer 06/30/2009 - (DGNews)
    Protein-Bound Paclitaxel Suspension Approved in Quebec for Metastatic Breast Cancer - (DGNews)
    TopAbstracts in Breast Cancer 06/23/2009 - (DGNews)
    TopAbstracts in Breast Cancer 06/16/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Breast Cancer
  • Optimizing the Use of Chemotherapy as the Backbone of Breast Cancer Treatment: An Update of the Latest Evidence
  • Applying Key Biomarkers in Oncology: From Biospecimen Preparation and Storage to Clinical Implications
  • Finding Ways to Prevent, Circumvent, or Overcome Cardiovascular Toxicity Associated With Modern Breast Cancer Therapies
  • Cutaneous Metastasis of Breast Carcinoma Presenting as Alopecia Neoplastica

    Webcasts/CME archive

     Recent cases - Breast Cancer
      Bilateral Swollen Eyelids Occurring During Adjuvant Treatment with Tamoxifen for Early Breast Cancer
      Ruptured Gallbladder as the First Presentation of Breast Cancer
      Synchronous Infiltrating Ductal Carcinoma and Primary Extramedullary Plasmacytoma of the Breast
      Primary Anaplastic Large Cell Lymphoma of the Breast Arising in Reconstruction Mammoplasty Capsule of Saline Filled Breast Implant after Radical Mastectomy for Breast Cancer: An Unusual Case Presentation
      The Radiologic Workup of a Palpable Breast Mass

      Cases archive
        




      my personal edition > breast cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Positive Effects of Herceptin on Breast Cancer Outcomes Unrelated to Cardiac Dysfunction: Presented at SABCS

      By Robert H. Carlson

      SAN ANTONIO, TX -- December 13, 2001 -- The monoclonal antibody Herceptin (trastuzumab) can enhance the clinical benefit of chemotherapy in women with advanced breast cancer.

      The benefits of Herceptin extend even to those women who develop cardiac dysfunction, according to researchers at the University of California at San Francisco (UCSF), in San Francisco, California, and Memorial Sloan-Kettering Cancer Center, in New York, New York.

      Publication in 1998 of a pivotal trial on Herceptin, which led to the drug's approval in the United States, established its positive effects on time to progression, response, and survival, when used with chemotherapy in women with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2).

      That trial also showed that Herceptin treatment was associated with cardiac dysfunctions, such as congestive heart failure and decreased left-ventricular ejection fraction.

      However, a new retrospective analysis of the pivotal 1998 trial has found that clinical improvements in women taking the drug occurred despite any development of cardiac dysfunction.

      Debu Tripathy, MD, an associate professor of medicine at UCSF and first author of the new study, reported on the outcomes of 469 patients at the 24
      th Annual San Antonio Breast Cancer Symposium, in San Antonio, Texas.

      In the original trial, he noted, cardiac dysfunction occurred at greatest frequency (27 percent) in patients simultaneously receiving an anthracycline and Herceptin, compared with 8 percent in patients receiving an anthracycline alone. Cardiac dysfunction was less common and less severe in patients treated with paclitaxel and Herceptin -- 13 percent versus 1 percent of patients receiving paclitaxel alone.

      In the latest study, Dr. Tripathy and colleagues found that 75 percent of patients who experienced cardiac dysfunction improved with treatment for congestive heart failure, and 77 percent of these patients continued to receive treatment for a median of 25 weeks.

      Thirty-three patients who developed cardiac dysfunction continued to receive Herceptin, and 64 percent of these patients did not experience further deterioration of cardiac dysfunction.

      Dr. Tripathy said therapy with Herceptin improved time to cancer-treatment failure even in patients with New York Heart Association (NYHA) grade 3 or 4 cardiac dysfunction, which did not improve to less than grade 3 with treatment.

      "These results suggest that risk-benefit considerations in the metastatic disease setting favor the use of Herceptin plus paclitaxel in this patient population," Dr. Tripathy concluded.




      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send